Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
Thomas Jefferson University
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Pfizer
OHSU Knight Cancer Institute
Prelude Therapeutics
Bellicum Pharmaceuticals
Rutgers, The State University of New Jersey
Cellphire Therapeutics, Inc.
Kiadis Pharma
Kiadis Pharma
M.D. Anderson Cancer Center
Cellectis S.A.
Incyte Corporation
CureOne
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
University of Arizona
St. Jude Children's Research Hospital
Celgene
H. Lee Moffitt Cancer Center and Research Institute
University of Virginia
University of California, San Francisco
University of California, San Francisco
Novartis